Endocrine Abstracts

Objective: Hypothyroidism is one of the most common disturbances of thyroid function caused by a thyroid hormone deficiency, found predominantly in young women. The general slowdown of metabolic processes and low-grade chronic inflammatory state occurs in the broad spectra of clinical hypothyroidism manifestations. Although several risk factors of hypothyroidism have been identified, the exact pathogenic mechanisms remain unexplained. The conventional treatment of hypothyroidi...

Gliomas are a highly heterogeneous group of brain tumours that are refractory to treatment, and highly invasive. The treatment and prognosis depend upon the tumor grade. Treatment of Grade II/III gliomas typically consists of maximal safe resection, followed by external beam radiation therapy. Although less aggressive than GBM, mortality is high with a 5-year survival rate of only 25.9%. Glioma tumors has been demonstrated NK-1 receptor system and substance P can be used as a ...

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....

In the 1980 s the discovery of expression of somatostatin receptors on NET cells made the use of somatostatin analogues in diagnosis and therapy possible.The aim: Of the study was to assess response of targeted radio-nuclide therapy with radio-labelled somatostatin analogue 90Y-[DOTA0,D-Phe1,Tyr3]-octreotate (DOTATATE) in treatment of disseminated NETs.Material and methods: 12 patients (a...

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...